Abstract | PURPOSE: PATIENTS AND METHODS: Seventy-five eligible patients were randomized to receive either CEOP or CEOP plus semustine followed by involved-field radiotherapy. RESULTS: The overall response rate of induction chemotherapy was 57.9% in CEOP arm compared with 62.2% in CEOP plus semustine arm (P=0.71). With a median follow-up of 30.1 months, 2-year overall survival was 73.3% and 62.2%, respectively (P=0.37). Toxicities in both arms were comparable and manageable. Through univariate and multivariate analysis, PS of 2, Stage II(E) and elevated LDH level were identified to be adverse prognostic factors. A new prognostic index categorized three groups of patients (low risk, no adverse factors; intermediate risk, one factor; and high risk, 2 or 3 factors) with highly significant difference of prognosis. Two-year overall survival was 87.5%, 60.6% and 30%, respectively (P=0.0002). CONCLUSIONS: The addition of semustine to CEOP regimen was not associated with improved efficacy. More effective treatment needs to be explored in patients with intermediate or high risk.
|
Authors | Xuejun Ma, Ye Guo, Ziqiang Pang, Biyun Wang, Hongfen Lu, Ya-Jia Gu, Xiaomao Guo |
Journal | Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
(Radiother Oncol)
Vol. 93
Issue 3
Pg. 492-7
(Dec 2009)
ISSN: 1879-0887 [Electronic] Ireland |
PMID | 19782419
(Publication Type: Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Semustine
- Epirubicin
- Vincristine
- Cyclophosphamide
- Prednisone
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, adverse effects, therapeutic use)
- Cyclophosphamide
(administration & dosage, adverse effects)
- Epirubicin
(administration & dosage, adverse effects)
- Female
- Humans
- Lymphoma, Extranodal NK-T-Cell
(drug therapy, mortality, radiotherapy)
- Male
- Middle Aged
- Neoplasm Invasiveness
- Nose Neoplasms
(drug therapy, radiotherapy)
- Pharyngeal Neoplasms
(drug therapy, radiotherapy)
- Prednisone
(administration & dosage, adverse effects)
- Prognosis
- Radiation Injuries
- Semustine
(administration & dosage, adverse effects)
- Survival Rate
- Vincristine
(administration & dosage, adverse effects)
- Young Adult
|